Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer

Authors :: Tongfu Jia
Feng Ye
Xiaoyan Lin
Mei Wang
Zhong Xie
Yuxian Bai
Yifu He
Haijun Zhong
Guifang Zhang
Xiang-Yuan Wu
Wenying Deng
Likun Liu
Junsheng Wang
Lu Wen
Shukui Qin
Yi Ba
Yong Huang
Tienan Yi
Jianwei Yang
Jin Li
Source :: Journal of Clinical Oncology. 36:e16020-e16020
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e16020Background: Apatinib has been approved in China for patients (pts) with advanced or metastatic gastric and gastro-esophageal junction adenocarcinoma after at least two lines of systemic chemo...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
digestive, oral, and skin physiology
medicine.disease
digestive system diseases
Metastatic gastric cancer
stomatognathic diseases
chemistry.chemical_compound
chemistry
Internal medicine
medicine
Adenocarcinoma
Apatinib
business

Full Text Access

Tools